HER2-positive
0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Carisma TherapeuticsPA - Philadelphia
2 programsCT-0508PHASE_11 trial
CT-0525PHASE_11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Carisma TherapeuticsCT-0525
Carisma TherapeuticsCT-0508
Clinical Trials (2)
Total enrollment: 54 patients across 2 trials
CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors
Start: Jan 2024Est. completion: Mar 20266 patients
Phase 1Active Not Recruiting
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Start: Feb 2021Est. completion: Dec 202448 patients
Phase 1Active Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.